On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. In this first video of the series, Dr. Chad Pecot, MD joins us to discuss 'What is squamous lung cancer?'
For our 13th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss the stages of lung cancer.
For our 12th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss what a PET scan is.
For our 11th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss lung cancer subtypes.
For our 7th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the best treatment for frail patients with advanced NSCLC.
To many, the recent FDA approval of a combination of chemotherapy and concurrent immunotherapy for the vast majority of patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) probably seems like a great idea.
Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Ketki Patel, a Patient Financial Advocate in Seattle recently offered suggestions and helpful information for financial navigation during your cancer...
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life. November is Lung Cancer Awareness Month. What are you grateful for?
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.
Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib
Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.